PhaseBio Pharmaceuticals Inc: going-concern / distress — PhaseBio Chapter 11 plan confirmed; creditors ~1.6% recovery, equity zero

PhaseBio Pharmaceuticals Inc

Bankruptcy Court confirmed liquidation plan on June 26, 2024; all assets to Liquidation Trust.
General unsecured creditors expected ~1.6% recovery; equity holders expected no recovery.
All ~50.2M shares of common stock to be canceled on Effective Date of the Plan.
Company reported assets ~$2.7M and liabilities ~$41.9M in May 2024 operating report.
Plan includes releases for officers, directors, and certain service providers from claims.

Key facts

Extracted from this filing and checked against the source text.

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.9

PhaseBio Pharmaceuticals Inc entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2022-10-23).

Proceeding: chapter 11
Court: United States Bankruptcy Court for the District of Delaware
Petition: 2022-10-23

Exact text from the filing

On October 23, 2022, PhaseBio Pharmaceuticals, Inc. (the "Company" or the "Debtor") filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"), thereby commencing a Chapter 11 case (the "Chapter 11 Case") for the Company (Case No. 22-10995).

View on SEC.gov

Browse all distress & bankruptcy →

Source: SEC EDGAR

accession 0001193125-24-178615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.